147 related articles for article (PubMed ID: 34398413)
1. Liver Transplantation: A Safe and Definitive Alternative to Lifelong Nitisinone for Tyrosinemia Type 1.
Menon J; Shanmugam N; Valamparampil JJ; Hakeem A; Vij M; Jalan A; Reddy MS; Rela M
Indian J Pediatr; 2022 May; 89(5):438-444. PubMed ID: 34398413
[TBL] [Abstract][Full Text] [Related]
2. Live donor liver transplantation for type 1 tyrosinemia: An analysis of 15 patients.
Karaca CA; Yilmaz C; Farajov R; Iakobadze Z; Aydogdu S; Kilic M
Pediatr Transplant; 2019 Sep; 23(6):e13498. PubMed ID: 31155831
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma requiring liver transplantation in hereditary tyrosinemia type 1 despite nitisinone therapy and α1-fetoprotein normalization.
Bhushan S; Noble C; Balouch F; Lewindon P; Lampe G; Hodgkinson P; McGill J; Ee L
Pediatr Transplant; 2022 Nov; 26(7):e14334. PubMed ID: 35698261
[TBL] [Abstract][Full Text] [Related]
4. Hereditary tyrosinemia type 1 in Turkey: twenty year single-center experience.
Zeybek AC; Kiykim E; Soyucen E; Cansever S; Altay S; Zubarioglu T; Erkan T; Aydin A
Pediatr Int; 2015 Apr; 57(2):281-9. PubMed ID: 25223216
[TBL] [Abstract][Full Text] [Related]
5. Type 1 tyrosinemia in Finland: a nationwide study.
Äärelä L; Hiltunen P; Soini T; Vuorela N; Huhtala H; Nevalainen PI; Heikinheimo M; Kivelä L; Kurppa K
Orphanet J Rare Dis; 2020 Oct; 15(1):281. PubMed ID: 33046095
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of dynamic thiol/disulfide homeostasis in hereditary tyrosinemia type 1 patients.
Aktuglu Zeybek AC; Kiykim E; Neselioglu S; Iscan HZ; Zubarioglu T; Cansever MS; Erel O
Pediatr Res; 2022 Aug; 92(2):474-479. PubMed ID: 34628487
[TBL] [Abstract][Full Text] [Related]
7. Nitisinone in the treatment of hereditary tyrosinaemia type 1.
McKiernan PJ
Drugs; 2006; 66(6):743-50. PubMed ID: 16706549
[TBL] [Abstract][Full Text] [Related]
8. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec.
Larochelle J; Alvarez F; Bussières JF; Chevalier I; Dallaire L; Dubois J; Faucher F; Fenyves D; Goodyer P; Grenier A; Holme E; Laframboise R; Lambert M; Lindstedt S; Maranda B; Melançon S; Merouani A; Mitchell J; Parizeault G; Pelletier L; Phan V; Rinaldo P; Scott CR; Scriver C; Mitchell GA
Mol Genet Metab; 2012 Sep; 107(1-2):49-54. PubMed ID: 22885033
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study.
Spiekerkoetter U; Couce ML; Das AM; de Laet C; Dionisi-Vici C; Lund AM; Schiff M; Spada M; Sparve E; Szamosi J; Vara R; Rudebeck M
Lancet Diabetes Endocrinol; 2021 Jul; 9(7):427-435. PubMed ID: 34023005
[TBL] [Abstract][Full Text] [Related]
10. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1.
Santra S; Baumann U
Expert Opin Pharmacother; 2008 May; 9(7):1229-36. PubMed ID: 18422479
[TBL] [Abstract][Full Text] [Related]
11. Nitisinone: new drug. Type 1 tyrosinemia: an effective drug.
Prescrire Int; 2007 Apr; 16(88):56-8. PubMed ID: 17458044
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of pre-symptomatic nitisinone treatment on long-term outcomes in Tyrosinemia type 1 patients: a systematic review.
Geppert J; Stinton C; Freeman K; Fraser H; Clarke A; Johnson S; Sutcliffe P; Taylor-Phillips S
Orphanet J Rare Dis; 2017 Sep; 12(1):154. PubMed ID: 28893311
[TBL] [Abstract][Full Text] [Related]
13. Late Development of Hepatocellular Carcinoma in Tyrosinemia Type 1 Despite Nitisinone (NTBC) Treatment.
Almuqbil M; Knoll J; Chinsky JM
J Pediatr Gastroenterol Nutr; 2020 Aug; 71(2):e73-e75. PubMed ID: 32141999
[No Abstract] [Full Text] [Related]
14. Tyrosinemia type 1: metastatic hepatoblastoma with a favorable outcome.
Nobili V; Jenkner A; Francalanci P; Castellano A; Holme E; Callea F; Dionisi-Vici C
Pediatrics; 2010 Jul; 126(1):e235-8. PubMed ID: 20547648
[TBL] [Abstract][Full Text] [Related]
15. Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function.
Bartlett DC; Lloyd C; McKiernan PJ; Newsome PN
J Inherit Metab Dis; 2014 Sep; 37(5):745-52. PubMed ID: 24515874
[TBL] [Abstract][Full Text] [Related]
16. HCC prevalence and histopathological findings in liver explants of patients with hereditary tyrosinemia type 1.
Seda Neto J; Leite KM; Porta A; Fonseca EA; Feier FH; Pugliese R; Miura IK; Chapchap P; Porta G
Pediatr Blood Cancer; 2014 Sep; 61(9):1584-9. PubMed ID: 24852359
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of liver transplantation in malignant liver tumors associated with tyrosinemia: clinical and laboratory findings of five cases.
Büyükpamukçu M; Varan A; Haberal M; Büyükpamukçu N; Köksal Y; Coşkun T; Yüce A; Kale G; Akyüz C; Kutluk T
Pediatr Transplant; 2006 Jun; 10(4):517-20. PubMed ID: 16712614
[TBL] [Abstract][Full Text] [Related]
18. A Lithuanian Case of Tyrosinemia Type 1 with a Literature Review: A Rare Cause of Acute Liver Failure in Childhood.
Rokaitė R; Čibirkaitė A; Zeleckytė V; Lazdinytė G; Dženkaitis M
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256395
[TBL] [Abstract][Full Text] [Related]
19. Living-donor liver transplantation for children with tyrosinemia type I.
Liu Y; Luo Y; Xia L; Qiu BJ; Zhou T; Feng MX; Xue F; Chen XS; Han LS; Zhang JJ; Xia Q
J Dig Dis; 2020 Mar; 21(3):189-194. PubMed ID: 31953907
[TBL] [Abstract][Full Text] [Related]
20. [Clinical follow up of Chilean patients with tyrosinemia type 1 treated with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-ciclohexanedione (NTBC)].
Raimann E; Cornejo V; Arias C; Cabello JF; Castro G; Fernández E; de la Parra A
Rev Med Chil; 2012 Feb; 140(2):169-75. PubMed ID: 22739945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
